Please login to the form below

Not currently logged in
Email:
Password:

RA

This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Amgen’s Riabni combination granted FDA approval for rheumatoid arthritis

Patients living with RA experience flare-ups or flares, where their symptoms can become worse. ... RA, showing no clinically significant differences in safety or efficacy based on comparative analytical, non-clinical and clinical data.

Latest news

More from news
Approximately 9 fully matching, plus 156 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Similar retrospective positive findings were recently published for the anti-diabetic, glucagon-like peptide-1 receptor agonist (GLP1-RA), which was also found to reduce neuroinflammation.

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    and Rheumatoid Arthritis (RA). ... More than 400, 000 people in the UK live with RA (around 380, 000 in England), and it is recognised as a condition that can cause debilitating physical pain, affect mental

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).

  • European CTR implementation advances ethical assessment of clinical trials European CTR implementation advances ethical assessment of clinical trials

    Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC

More from intelligence
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 31 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...
Animation: Living With
The journey from the patient's perspective...